Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Kater, Arnon P., van Oers, Marinus H.J., van Norden, Yvette, van der Straten, Lina, Driessen, Julia, Posthuma, Ward F.M., Schipperus, Martin, Chamuleau, Martine E.D., Nijland, Marcel, Doorduijn, Jeanette K., Van Gelder, Michel, Hoogendoorn, Mels, De Croon, Francien, Wittebol, Shulamiet, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Schaafsma, Martijn R., Dobber, Johan A., Kersting, Sabina, Levin, Mark-David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312018/
https://www.ncbi.nlm.nih.gov/pubmed/30115656
http://dx.doi.org/10.3324/haematol.2018.193854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312018/
https://www.ncbi.nlm.nih.gov/pubmed/30115656
http://dx.doi.org/10.3324/haematol.2018.193854

Ejemplares similares